2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1001

Cytomegalovirus Reactivation in Connective Tissue Disease By Immunosuppressive Therapy Predicts Severe Infection and High Mortality
Abstract Number: 98

Daily Symptom Reports in a Smartphone-Based Study ‘Cloudy with a Chance of Pain’: Patterns of Attrition over the First Six Months
Abstract Number: 2747

Dapsa-28 May be Used Instead of Dapsa-66/68 in Psoriatic Arthritis
Abstract Number: 2206

Data on Treatment from Brazilian Fibromyalgia Patients Registry (EpiFibro)
Abstract Number: 1553

Declining Flare Rates in the First Five Years of RA Disease, but Not after
Abstract Number: 1201

Deconvolution of Immune Cell Proportions from Whole Blood RNA Using Next-Generation Sequencing
Abstract Number: 1531

Decrease in Bone Mineral Density during Three Months of Early RA Measured By DXR Predicts Radiographic Joint Damage after One Year
Abstract Number: 1636

Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study
Abstract Number: 1089

Decreased B Cell Activation-Induced Apoptosis in Cells Overexpressing Interferon Regulatory Factor 5 (IRF5), a Gene Associated with Risk for Systemic Lupus Erythematosus and Other Autoimmune Diseases
Abstract Number: 2292

Decreased Endothelial and Smooth Muscle Responsiveness in the Vasculature of Gout Patients Compared with Healthy Controls: Relationship Between Flow- and Nitrate-Mediated Dilation, Serum Urate and CRP
Abstract Number: 2705

Decreased Expression of Autophagy Genes and Their Association with Spinal Damage in Patients with Ankylosing Spondylitis
Abstract Number: 3232

Decreased Expression of Micro-RNA 130a and Micro-RNA 708 in Type-1 Classical Dendritic Cells of Patients with Primary SS Indicates Their Dysregulation
Abstract Number: 1852

Decreased Expression of Sirtuin 7 By Lung Fibroblasts from Patients with Scleroderma Contributes to Elevated Collagen Production
Abstract Number: 658

Decreased Expression of Ten Micro-RNAs in Plasmacytoid Dendritic Cells of Patients with Primary SS Indicates Dysregulation on Multiple Levels
Abstract Number: 2304

Decreased Occurrence of Colon Cancer Among Gout Patients: Assessment By Physician Diagnosis and Colonoscopy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].